Manipulation of the Th1/Th2 balance in autoimmune disease

doi:10.1016/S0952-7915(96)80013-6

Current Opinion in Immunology

Volume 8, Issue 6, December 1996, Pages 837-842

https://doi.org/10.1016/S0952-7915(96)80013-6 Get rights and content

Abstract

Many autoimmune diseases are caused by autopathogenic Th1 cells. Because in vitro Th1 and Th2 cells cross-regulate each other, it is likely that the induction of self-antigen-specific Th2 cells can prevent autoimmune disease. In the past year, investigators have further defined the role of Th1 and Th2 cytokines in the induction and regulation of autoimmunity. Furthermore, the role of MHC—antigen—T-cell avidity (strength of signal) in inducing such protective immune responses has been elucidated.

References (62)

WE Paul et al.
Lymphocyte responses and cytokines
Cell
(1994)
Y Chen et al.
Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis
Science
(1994)
A Miller et al.
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering
Proc Natl Acad Sci USA
(1992)
M Brunner et al.
Altered Th1/Th2 balance associated with the immunosuppressive/protective effect of the H-2A^b allele on the response to allo-4-hydoxyphenylpyruvate dioxygenase
Eur J Immunol
(1995)
LB Nicholson et al.
An altered peptide ligand mediates immune deviation and prevents experimental autoimmune encephalomyelitis
Immunity
(1995)
SJ Khoury et al.
Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor-β, interleukin 4, and prostaglandin E expression in the brain
J Exp Med
(1992)
TR Mosmann et al.
Two types of murine helper T cell clones
J Immunol
(1986)
CA Janeway et al.
CD4⁺ T cells: specificity and function
Immunol Rev
(1988)
A Sher et al.
Regulation of immunity to parasites and T cell-derived cytokines
Annu Rev Immunol
(1992)
S Romagnani
Lymphokine production by human T cells in disease states
Annu Rev Immunol
(1994)

RP Bucy et al.

Heterogeneity of single cell cytokine gene expression in clonal T cell populations

J Exp Med

(1994)

RP Bucy et al.

Single cell analysis of cytokine gene expression during CD4⁺ T-cell phenotype development

Proc Natl Acad Sci USA

(1995)

P Openshaw et al.

Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations

J Exp Med

(1995)

A Kelso

Th1 and Th2 subsets: paradigms lost?

Immunol Today

(1996)

E Murphy et al.

Reversibility of T helper 1 and 2 populations is lost after long-term stimulation

J Exp Med

(1996)

SS Zamvil et al.

The T lymphocyte in experimental allergic encephalomyelitis

Annu Rev Immunol

(1990)

VK Kuchroo et al.

Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis

J Immunol

(1993)

JD Katz et al.

T helper cell subsets in insulin-dependent diabetes

Science

(1995)

FS Wong et al.

CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset diabetes in NOD mice in the absence of CD4 cells

J Exp Med

(1996)

VK Kuchroo et al.

B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy

Cell

(1995)

A Khoruts et al.

Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells

J Immunol

(1995)

IA Ferber et al.

Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)

J Immunol

(1996)

B Hultgren et al.

Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice

Diabetes

(1996)

MK Racke et al.

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

J Exp Med

(1994)

M Rocken et al.

IL-4 induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease

Immunol Today

(1996)

M Moritani et al.

Transgenic expression of IL-10 in pancreatic islet a cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice

Int Immunol

(1994)

L Wogensen et al.

Production of interleukin-10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice

J Exp Med

(1994)

M Lee et al.

IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity

J Exp Med

(1996)

A Miller et al.

Antigen-driven bystander suppression after oral administration of antigen

J Exp Med

(1991)

F Powrie et al.

A critical role for transforming growth factor β- but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB^low CD4⁺ T cells

J Exp Med

(1996)

ME Neurath et al.

Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance

J Exp Med

(1996)

Cited by (171)

Innately versatile: γδ17 T cells in inflammatory and autoimmune diseases
2018, Journal of Autoimmunity
IL-17-producing γδ (γδ17) T cells form a versatile subset of cells that respond rapidly to innate stimuli and support the pro-inflammatory functions of different myeloid and lymphoid lineages, being particularly critical in the early stages of inflammatory and autoimmune responses. In mice, under homeostatic conditions, these innate-like lymphocytes are pre-programmed in the fetal thymus, through an intricate process involving both T cell receptor-dependent and -independent signals, which allows them to readily produce IL-17 upon stimulation. However, given their transcriptional and epigenetic wiring, γδ17 T cells are permissive to different environmental instructions, and can readily acquire the ability to co-produce multiple cytokines, such as IFN-γ, IL-22 and GM-CSF, that further propagate inflammation. Moreover, strong IL-23 signals, which are abundantly found in autoinflammatory conditions, are able to induce de novo differentiation of γδ17 T cells from uncommitted precursors, both in mice and humans. This notwithstanding, the exact mechanisms responsible for γδ17 T cell pathogenicity and multifunctionality are still poorly understood, especially in humans. The pathogenic roles attributed to γδ17 T cells in autoimmune diseases stem mainly from their ability to recruit different inflammatory myeloid populations to the target tissue, and to modulate αβ T cell function, either by enhancing inflammatory T_H17 responses, or by restraining regulatory T_reg cell activity. Given their capacity to link key inflammatory axes of innate and adaptive immunity, a better understanding of the molecular basis underpinning γδ17 T cell plasticity, and how much this feature accounts for their pathophysiological roles, may be critical for developing novel therapeutic approaches. In this review, we discuss the importance of γδ17 T cells in breaking tolerance and enhancing inflammation in various autoimmune diseases, such as multiple sclerosis, psoriasis and rheumatoid arthritis under the light of their basic biological traits, e.g. development, activation, effector functions and plasticity.
Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis
2014, Journal of Autoimmunity
Citation Excerpt :
The Th1-type cells secrete pro-inflammatory cytokines, mainly IL-2 and IFN-γ; the Th2-type cells produce among others IL-4 and IL-10. While Th1-type cytokines are thought to play a critical role in the pathogenesis of autoimmune diseases [61] including EAMG [62,63], by facilitating the production of complement activating IgG2b isotypes [64,65], while the Th2 cytokines have been shown to be protective in EAMG [66,67] by facilitating the production of non-complement activating IgG1 antibodies [64,65]. Apart from Th2 cells, tolerogenic DCs are also known to express high amounts of IL-10 and TGF-β [68], and induce/expand Tregs in vitro and in vivo [69].
Myasthenia gravis (MG) is an autoimmune disorder caused by target-specific pathogenic antibodies directed toward postsynaptic neuromuscular junction (NMJ) proteins, most commonly the skeletal muscle nicotinic acetylcholine receptor (AChR). In MG, high-affinity anti-AChR Abs binding to the NMJ lead to loss of functional AChRs, culminating in neuromuscular transmission failure and myasthenic symptoms. Intravenous immune globulin (IVIg) has broad therapeutic application in the treatment of a range of autoimmune diseases, including MG, although its mechanism of action is not clear. Recently, the anti-inflammatory and anti-autoimmune activities of IVIg have been attributed to the IgG Fc domains. Soluble immune aggregates bearing intact Fc fragments have been shown to be effective treatment for a number of autoimmune disorders in mice, and fully recombinant multimeric Fc molecules have been shown to be effective in treating collagen-induced arthritis, murine immune thrombocytopenic purpura, and experimental inflammatory neuritis. In this study, a murine model of MG (EAMG) was used to study the effectiveness of this novel recombinant polyvalent IgG2a Fc (M045) in treating established myasthenia, with a direct comparison to treatment with IVIg. M045 treatment had profound effects on the clinical course of EAMG, accompanied by down-modulation of pathogenic antibody responses. These effects were associated with reduced B cell activation and T cell proliferative responses to AChR, an expansion in the population of FoxP3⁺ regulatory T cells, and enhanced production of suppressive cytokines, such as IL-10. Treatment was at least as effective as IVIg in suppressing EAMG, even at doses 25–30 fold lower. Multimeric Fc molecules offer the advantages of being recombinant, homogenous, available in unlimited quantity, free of risk from infection and effective at significantly reduced protein loads, and may represent a viable therapeutic alternative to polyclonal IVIg.
Communication between pathogenic T cells and myeloid cells in neuroinflammatory disease
2013, Trends in Immunology
Citation Excerpt :
Based on mostly circumstantial data from EAE, it was initially thought that autoreactive interferon (IFN)-γ-producing TH1 cells were responsible for the inflammation observed in MS and that THPath cells are in fact TH1 cells [4]. Conversely, TH2 cells were assumed to have some regulatory function in neuroinflammatory disease, and deviation of TH1 response towards the TH2 signature was proposed as a therapeutic strategy to fight MS [37,38]. In fact, most of the approved drugs for the treatment of MS were accredited for their properties of deviating a presumably damaging TH1 immune response towards a protective TH2 response, also through the induction of anti-inflammatory APCs as a vehicle for T cell immune modulation [39].
Clinical and experimental data suggest that T helper (T_H) cells are involved in the pathogenicity of experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS), but it is unlikely that they are directly responsible for the observed demyelination and axonal loss. Instead, the cell population that targets the destruction of oligodendrocytes and axons, and the mechanism exploited by central nervous system (CNS)-invading encephalitogenic T_H cells to instruct these cells to mediate tissue damage, are still under debate. Mature myeloid cells form a prominent component of the neuroinflammatory infiltrates and are the suspected culprits behind the CNS injury due to their arsenal of toxic factors. Here, we describe the process of encephalitogenic T_H cell activation followed by their entry into the CNS and discuss how pathogenic T_H cells influence the myeloid compartment.
Icaritin inhibits T cell activation and prolongs skin allograft survival in mice
2012, International Immunopharmacology
Icaritin is a native compound from Epimedium Genus, a traditional Chinese herbal medicine which is effective in treating asthma, autoimmune diseases and viral infections. In the present paper, the immunosuppressive effects of icaritin were found through in vitro and in vivo studies. Icaritin could dose-dependently inhibit murine CD4⁺ T cells proliferation stimulated with mitogens or specific antigen ovabumin (OVA). Icaritin at 0.25–25 μM could down-regulate T cell activation marker CD25 expression and inhibit IL-2 production. It could also reduce the Th1 cytokine IFN-γ production significantly if the T cells were activated by ConA or anti-CD3; while the inhibition of IL-4 secretion was only seen on anti-CD3 activated T cells treated with low concentrations of icaritin. In vivo study showed that treatment of icaritin at 10 mg/kg/day on mice could suppress the immune response with prolonged allograft skin survival. Further study demonstrated that it reduced the alloantigen-induced splenocytes proliferation and Th1/Th2 cytokines. It could also increase NF-AT luciferase activity in Jurkat-NF-AT-luc T cells. The above results suggested that icaritin might be used to treat Th1 dominated immune diseases by interfering T cells activation with mechanism different to CsA.
Decreased interferon-α production in response to CpG DNA dysregulates cytokine responses in patients with multiple sclerosis
2012, Clinical Immunology
Type I interferons (IFNs), represented by IFN-α and β, activate immune effector cells belonging to the innate and adaptive immune systems. Plasmacytoid dendritic cells (pDCs) produce IFN-α in response to CpG DNA. We aimed to examine the impact of pDC-produced IFN-α on the adaptive immune system in Multiple Sclerosis (MS). Our results demonstrated that CpG DNA-induced IFN-α production was significantly decreased in PBMCs from MS patients. Decreased levels of IL-12 p70, IFN-γ, and IL-17 and increased level of IL-10 were found in CpG DNA-treated PBMCs of healthy subjects unlike in those from MS patients. In samples pre-treated with IFN-α and IFN-β, decreased levels of IL-12 p70, IFN-γ, and IL-17 and increased level of IL-10 were detected in PBMCs from MS patients. These results suggest that CpG DNA-induced decreased IFN-α production causes pro-inflammatory cytokine secretion, and either IFN-α or IFN-β induces anti-inflammatory cytokine secretion in the adaptive immune system in MS.
Chimeric antigen receptor T-cell therapy beyond cancer: Current practice and future prospects
2020, Immunotherapy

View all citing articles on Scopus

View full text

Manipulation of the Th1/Th2 balance in autoimmune disease

Abstract

Cell

Science

Proc Natl Acad Sci USA

Eur J Immunol

Immunity

J Exp Med

Two types of murine helper T cell clones

J Immunol

CD4+ T cells: specificity and function

Immunol Rev

Regulation of immunity to parasites and T cell-derived cytokines

Annu Rev Immunol

Lymphokine production by human T cells in disease states

Annu Rev Immunol

Heterogeneity of single cell cytokine gene expression in clonal T cell populations

J Exp Med

Single cell analysis of cytokine gene expression during CD4+ T-cell phenotype development

Proc Natl Acad Sci USA

Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations

J Exp Med

Th1 and Th2 subsets: paradigms lost?

Immunol Today

Reversibility of T helper 1 and 2 populations is lost after long-term stimulation

J Exp Med

The T lymphocyte in experimental allergic encephalomyelitis

Annu Rev Immunol

Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis

J Immunol

T helper cell subsets in insulin-dependent diabetes

Science

CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset diabetes in NOD mice in the absence of CD4 cells

J Exp Med

B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy

Cell

Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells

J Immunol

Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)

J Immunol

Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice

Diabetes

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

J Exp Med

IL-4 induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease

Immunol Today

Transgenic expression of IL-10 in pancreatic islet a cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice

Int Immunol

Production of interleukin-10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice

J Exp Med

IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity

J Exp Med

Antigen-driven bystander suppression after oral administration of antigen

J Exp Med

A critical role for transforming growth factor β- but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlow CD4+ T cells

J Exp Med

Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance

J Exp Med

CD4⁺ T cells: specificity and function

Single cell analysis of cytokine gene expression during CD4⁺ T-cell phenotype development

A critical role for transforming growth factor β- but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB^low CD4⁺ T cells